Introduction
============

Human HTT is a large protein of approximately 350 kDa made up of 3144 amino acids. It is nearly ubiquitously expressed with the highest level of expression in the brain and the testes. The size and predicted structure of the protein suggest its role as a protein scaffold that coordinates a multitude of cellular functions (reviewed in [@B47]). Studies have reported pro-survival properties of wild type Htt. It protects cells from cell death induced by a variety of stimuli including serum withdrawal ([@B45]), mutant Htt ([@B25]), and NMDA receptor-mediated excitotoxicity ([@B26]). Htt has effects on gene transcription by binding to transcriptional regulators such as the repressor RE1-silencing transcription factor ([@B66]), p53 and CREB-binding protein ([@B52]), NeuroD ([@B31]), NF-κB ([@B55]) and transcriptional activator Sp1 and co-activator TAF~II~130 ([@B16]). Htt is involved in transport of a variety of vesicles including brain-derived neurotrophic factor-containing vesicles ([@B19]), synaptic precursor vesicles ([@B63]), and GABA receptor-containing vesicles ([@B57]). Htt coordinates cell division through the regulation of spindle pole assembly during mitosis ([@B21]; [@B18]). Moreover, Htt is reported involved in ciliogenesis ([@B24]), endosomal trafficking ([@B43]), and autophagy ([@B23]; [@B44]).

Wild type Htt is essential for embryonic development as knockout of *Htt* in mice results in embryonic death at day 7.5 ([@B17]; [@B38]; [@B64]). Htt may be needed for neurogenesis as reduced expression of wild type Htt causes impaired brain development and abnormal vascular morphogenesis in mice ([@B61]). Others reported cells without Htt can be differentiated into functional neurons ([@B33]) or glial cells ([@B12]). Thus, Htt's role in neural development remains unclear.

Abnormal neurogenesis has been observed in HD. Increased cell proliferation and neurogenesis were found in human postmortem HD brains ([@B13]), and in the quinolinic acid lesion rat model of HD ([@B56]). Similarly, mutant Htt caused faster neuronal differentiation of embryonic and NSCs *in vitro* ([@B29]). In contrast, reduced hippocampal neurogenesis was observed in R6/2 transgenic HD mice ([@B20]). Increasing evidence suggests mutant Htt causes dysregulated neurogenesis. In the HD R6/2 mice, expansion of striatal NSCs and altered migration of neural progenitor cells into the striatum were observed ([@B5]). A study reported that Q111 Htt knock-in mice (with glutamine repeats expanded to 111) exhibited defects in specification and maturation of striatal medium spiny neurons ([@B35]). Mutant Htt was also shown to affect cortical development by causing spindle misorientation in dividing cortical progenitors ([@B36]). Selective expression of mutant Htt in mice up to postnatal day 21 resulted in impairment similar to mice expressing mutant Htt throughout life ([@B34]). Furthermore, mice expressing very low levels of Htt up to postnatal day 21 also exhibited late-life neurodegeneration phenotypes ([@B4]). These studies suggest developmental abnormalities resulting from early mutant Htt expression or very low Htt expression may contribute to the pathogenesis of HD.

Neural stem cells derived from HD mice, or ES cells expressing mutant Htt or no Htt (*Htt-*null) have been studied for growth, motility, and biochemical properties ([@B46]). Interestingly, NS cells derived from HD mouse brains showed reduced levels of cholesterol, increased reactive oxygen species, and impaired motility compared with NS cells from wild type animals, recapitulating phenotypes seen in HD patients. In contrast, *Htt* knockout (KO) NS cells derived from *Htt*-KO ES cells had increased cholesterol levels. Nguyen et al. used a neural induction culture model to examine stages of neural induction in ESCs expressing mutant Htt or in *Htt*-KO ESCs ([@B39]). They reported disruption of proliferation, self-renewal, and the specification of NSCs in *Htt*-KO cells while mutant Htt enhanced neurogenesis. *Htt*-KO NSCs also showed increased endodermal and mesodermal gene expression suggesting Htt may be involved in neural and non-neural fate decisions. The same group also examined lineage differentiation of *Htt*-KO ESCs and ESCs expressing mutant Htt ([@B40]). They found Htt required in the differentiation of ESCs into ectoderm, endoderm, and mesoderm while mutant Htt differentially impaired stage-specific developmental events.

Recent investigations on how mutant Htt affects neural development as well as the role of wild type Htt in neural development suggest neurodegeneration may result from both gain of toxic mutant Htt function and loss of wild type Htt function. In this study, we used the 5-stage differentiation protocol ([@B48]) to differentiate mouse ESCs lacking *Htt* to different cell lineages and examined the role of Htt in progenitor cell differentiation. We found Htt is required for ectoderm, but not mesoderm or endoderm differentiation under our experimental conditions.

Materials and Methods {#s1}
=====================

Mouse Embryonic Stem Cell Culture
---------------------------------

Four mESC lines used in this study are generous gifts of Dr. Scott O. Zeitlin (University of Virginia). They are: (1) R1, parental wild type ES cells; (2) *Htt*-null (HN), *Htt* nullizygous ES cells in which the promoter and exon 1 sequence of *Htt* were deleted ([@B64]); (3) 7Q, 3xFlag-Htt^7Q/7Q^ ES cells that express wild type Htt Flag-tagged at the N-terminus; (4) 140Q, heterozygous 3xFlag-Htt^140Q/7Q^ ES cells carrying an *Htt* allele with an expanded polyQ tagged with a 3xFLAG tag at the N-terminus ([@B65]).

Mouse embryonic stem cells were maintained undifferentiated on 0.1% gelatin-coated plates under feeder-free culture conditions in standard ES medium containing Dulbecco's minimal essential medium (DMEM, Cellgro) supplemented with 15% ES-Cult FBS (STEMCELL Technologies), 1X Penicillin--Streptomycin--Glutamine (P/S/Q), 1 mM sodium pyruvate, 1X non-essential amino acids (NEAA), and 0.1 mM β-mercaptoethanol (all from GIBCO), 10^3^ Units/ml ESGRO mouse Leukemia Inhibitory Factor (LIF, Millipore), and 2 μM SU 5402 (VEGFR and FGFR inhibitor; Tocris Bioscience), 0.8 μM PD184352, and 3 μM CHIR99021 (MEK and GSK3 inhibitors, respectively, both from BioVision). Standard ES medium was changed daily and cells were passaged every 2--3 days using 0.05% Trypsin/EDTA.

5-Stage Neural Cell Differentiation
-----------------------------------

Mouse embryonic stem cells were differentiated into neural cells according to the 5-stage neural differentiation protocol developed by Dr. Ronald D.G. McKay ([@B41]; [@B27]). Undifferentiated ES cells (Stage 1) were grown as described above for at least three passages before proceeding to the next stage.

To induce EBs formation (Stage 2), mESCs were dissociated into single-cell suspension with 0.05% trypsin/EDTA and plated onto 100 mm non-adherent bacterial petri dishes (2 × 10^6^ cells per dish) in the standard ES medium without LIF and the inhibitors. Floating EBs formed spontaneously were cultured for 4 days in suspension, collected and plated onto 100 mm tissue culture plates in the standard ES medium without LIF and the inhibitors.

After EBs attached to the culture plate began to differentiate (after 24 h), selection of nestin-positive cells (Stage 3) was initiated by replacing the standard ES medium with the serum-free ITSFn medium, which contained DMEM/Ham's F-12 50/50 (Cellgro) supplemented with 1X P/S/Q, 5 μg/ml insulin, 50 μg/ml human apo-transferrin, 30 nM selenium chloride, and 5 μg/ml fibronectin. ITSFn medium was replenished every 2 days.

After 8 days of selection, expansion of nestin-positive cells (Stage 4) was initiated. Briefly, cells were dissociated with 0.05% trypsin/EDTA and plated on poly-[L]{.smallcaps}-ornithine and laminin-coated tissue culture plates or glass coverslips at a density of 1.5--2 × 10^5^ cells per cm^2^ in the N2 medium containing DMEM/Ham's F-12 50/50 supplemented with 1X P/S/Q, 25 μg/ml insulin, 50 μg/ml human apo-transferrin, 30 nM selenium chloride, 20 nM progesterone, 100 μM putrescine, 10 ng/ml bFGF (R&D Systems), and 1 μg/ml laminin. Nestin-positive cells were expanded for 6 days. The medium was changed every 2 days.

Differentiation (Stage 5) was induced by withdrawing bFGF from the N2 medium. Cells were incubated under differentiation conditions for 6--15 days, changing the medium every 2 days.

Alkaline Phosphatase Staining
-----------------------------

Alkaline phosphatase staining was used to confirm undifferentiated mESCs. Cells cultured on 6-well plates were fixed in a fixative solution (citrate buffered acetone, 60%) for 30 s, and rinsed gently in deionized water. Cells were incubated in an alkaline-dye mixture, which contained Fast Blue RR Salt and Naphthol AS-MX Phosphate Alkaline Solution (Sigma-Aldrich) for 30 min at 37°C. Afterward, cells were rinsed thoroughly in deionized water, followed by examination under a microscope.

Immunocytochemistry
-------------------

Cells cultured on glass coverslips were fixed in 4% paraformaldehyde in PBS for 10 min, followed by permeabilization in PBS containing 0.25% Triton X-100 for 10 min. Blocking was carried out by incubation in 1% BSA in PBST (PBS + 0.1% Tween 20) for 30 min. Cells were incubated with primary antibodies for 2 h at room temperature. Following antibodies were used at indicated dilutions: mouse α-nestin (Millipore; 1:300), mouse α-β-III tubulin (Millipore; 1:400) and rabbit α-GFAP (Sigma-Aldrich; 1:400). Fluorescently labeled goat α-mouse/rabbit secondary antibody (1:500 for 1 h at room temperature) was applied to samples in the dark. Nuclear counterstaining was performed by incubating samples in 1 mM TO-PRO-3 (Invitrogen) in PBS for 20 min followed by confocal imaging.

Three Germ Layer Differentiation via Hanging-Drop EB Formation
--------------------------------------------------------------

Htt mESC lines were induced to differentiate into three germ layers (ectoderm, mesoderm, and endoderm). Differentiation protocols used involved hanging-drop EB formation ([@B48]) in which a defined number of mESCs was used to form one EB. In this way, all EBs generated would be of similar size. To make hanging-drop EBs, mESCs were maintained undifferentiated for at least three passages, followed by trypsinization and counting. Single-cell suspension containing defined mESC number (200, 500, and 600 cells/20 μl for neural, cardiac, and pancreatic differentiation, respectively) was prepared in the Differentiation Medium I consisting of Iscove's modification of DMEM (IMDM) supplemented with 20% ES-Cult FBS, 1X P/S/Q, 1 mM sodium pyruvate, 1X NEAA and 450 μM monothioglycerol (Sigma-Aldrich). On the lid of a 100 mm bacteriological Petri dish, about 60 droplets (20 μl per drop) of mESC suspension were placed. 10 ml of PBS was added to the dish. The lid was inverted and mESCs in hanging-drops were cultivated for 2--3 days. During this period, mESCs aggregated to form one EB within each droplet. Hanging-drop EBs were then incubated in suspension in the Differentiation Medium I for 2--3 days until the time of specific lineage differentiation. When collecting or transferring floating EBs, large orifice 200 μl tips were used to keep EBs intact.

Neural Progenitor Cell Differentiation
--------------------------------------

Neural EBs (200 mESCs per drop) were hung for 2 days before transferring to ultra-low attachment 96-well plate and EBs were further cultivated for 3 days. One EB was placed in one well so that size and morphology could be examined under a microscope. Day 5 EBs were collected and placed into a 24-well cell culture plate for attachment. After 1 day, NSC selection was started by switching the medium to ITSFn medium, followed by NSC expansion in the N2 medium. This corresponds to Stage 3 and Stage 4 of the 5-stage neural differentiation method described above.

Cardiac Progenitor Differentiation
----------------------------------

Cardiac EBs (500 mESCs per drop) were hung for 3 days before transferring to a 60 mm bacteriological Petri dish and cultured for 2 days in suspension. Day 5 EBs were placed in gelatin-coated 6-well plates (about 15 EBs per well) for attachment and differentiation in Differentiation Medium I. This was sufficient to drive cardiac differentiation as beating EBs were observed from both R1 and HN after 7 days. The medium was changed every 2 days for 2 weeks ([@B8]; [@B48]).

Pancreatic Progenitor Differentiation
-------------------------------------

Pancreatic EBs (600 mESCs per drop) were hung for 3 days before transferring to a 60 mm bacteriological Petri dish and cultured for 2 days in suspension. Day 5 EBs were plated on gelatin-coated 6-well plates for attachment and differentiation in Differentiation Medium I. The medium was changed every 2 days for 9 days. Cells were trypsinized and seeded onto poly-[L]{.smallcaps}-ornithine/laminin-coated plates in the pancreatic differentiation medium. The medium was composed of DMEM/F12 supplemented with 1X P/S/Q, 25 μg/ml insulin, 50 μg/ml human apo-transferrin, 30 nM selenium chloride, 20 nM progesterone, 100 μM putrescine, 1 μg/ml laminin, 2% B27 and 10 mM nicotinamide. The medium was changed every 2 days for 3 weeks ([@B7]; [@B48]).

In lineage differentiation experiments, cell morphology was monitored under a microscope throughout the differentiation protocol. Cells at different stages were collected for RNA extraction and progenitor-specific markers were detected by RT-PCR.

RNA Extraction, cDNA Synthesis, RT-PCR
--------------------------------------

Total RNA was extracted using TRI-Reagent (Sigma-Aldrich) followed by DNase-I treatment (Promega). For each sample, 1 μg of total RNA was used to synthesize cDNA using the First-Strand cDNA Synthesis Kit and 10X primer mix from USB (Affymetrix). qPCR was carried out on equal volumes of RT reactions using the 2X SYBR^®^ Green PCR Master Mix (Applied Biosystems). Cycling parameters used were: denaturation at 95°C for 30 s, annealing at 52--60°C for 40 s depending on primers, and elongation at 72°C for 45 s, for 45 cycles. qPCR data was calculated after normalization to GAPDH or 18S ribosomal RNA. Primer sequences are provided in Supplementary Table [1](#SM1){ref-type="supplementary-material"}.

Western Blot Analysis
---------------------

Mouse embryonic stem cells were lysed in total lysis buffer \[20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol, 1.5 mM MgCl~2~, 1 mM DTT, 1 mM PMSF, and 1X protease inhibitor cocktail\] and cell lysate extracted by centrifugation at 13,000 rpm for 30 min at 4°C. Protein concentrations were measured by Bradford assay (Bio-Rad). Fifty micrograms of total protein was loaded in each lane of an SDS-polyacrylamide gel.

Cytoplasmic and nuclear fractions were extracted using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology). From 20 μl of packed cells as starting material, about 200 μl of cytoplasmic fraction and 100 μl of nuclear fraction were obtained. Five percentage of total volume was loaded in each lane.

The following antibodies were used at the indicated dilution: rabbit α-Kdm6A (1:2000, Bethyl Laboratories), rabbit α-Olig2 (1:1000, Novus Biologicals), rabbit a-Vinculin (1:4000, Thermo Fisher Scientific), rabbit α-YY1 (1:2000, Santa Cruz Biotechnology), IRDye 680RD goat α-rabbit secondary antibody (1:10000, LI-COR Biosciences). Fluorescent signal was scanned using the LI-COR Odyssey machine.

Statistical Analysis
--------------------

Unless stated otherwise, values in the figures and text are presented as mean ± SEM. Statistical analysis was performed using Prism 7 (GraphPad Software). One-way analysis of variance (ANOVA) was used followed by Bartlett's test. ^∗∗∗∗^*P* \< 0.0001 represents statistical significance.

RNA-Seq
-------

Total RNA was isolated from three different batches of R1 and HN mESCs collected on different dates using the Direct-zol^TM^ RNA MiniPrep Kit (Zymo Research) according to the manufacturer's instructions. Bioanalyzer was used to determine RNA concentration and quality. One hundred and thirty nanograms of total RNA was used to construct RNA-Seq libraries using Illumina TruSeq RNA Library Preparation Kit v2 and 15 cycles of PCR amplification. Libraries were run on an Illumina HiSeq 2500 instrument using a paired end 50 protocol, rapid run flow cell.

Sequencing results were demultiplexed and converted to FASTQ format using Illumina bcl2fastq software. Reads were aligned to the mouse genome (build mm10/GRCm38) using the splice-aware STAR aligner ([@B14]). PCR duplicates were removed using the Picard toolkit^[1](#fn01){ref-type="fn"}^. HTSeq package ([@B2]) was utilized to generate counts for each gene based on how many aligned reads overlap its exons. These counts were then normalized and used to test for differential expression using negative binomial generalized linear models implemented by the DESeq2 R package ([@B30]). Additionally, differential exon usage analysis was performed using the DEXSeq R package ([@B3]). The RNA-seq data has been deposited to the NCBI GEO database with an accession number [GSE92905](GSE92905).

Results
=======

mESCs Lacking Htt Fail to Differentiate into Neural Stem Cells
--------------------------------------------------------------

We investigated potential role for wild type and mutant Htt in the differentiation of mESCs to cells of neural lineage. The four mESC lines tested were: wild type [R1]{.ul} ES cells, *Htt* nullizygous [HN]{.ul} ES cells ([@B64]), [7Q]{.ul} ES cells that express Flag-tagged wild type Htt (3xFlag-Htt^7Q/7Q^), heterozygous [140Q]{.ul} ES cells carrying an allele encoding Flag-tagged expanded polyQ Htt (3xFlag-Htt^140Q/7Q^) ([@B65]). Expression of Htt and pluripotency markers was verified by immunoblotting and RT-qPCR (Supplementary Figure [1](#SM2){ref-type="supplementary-material"}). The R1, HN, 7Q, and 140Q ES cells were differentiated into neurons/glia using the 5-stage neural differentiation method involving generation of massive EBs ([@B41]; [@B27]). mESCs (Stage 1) were cultured under feeder-free conditions and undifferentiated status confirmed by dark purple staining of ES colonies in the AP assay (**Figure [1A](#F1){ref-type="fig"}**). Floating EBs (Stage 2) were spontaneously generated after seeding mESCs to a non-adherent Petri dish. All four mESCs formed EBs of different sizes. HN mESCs formed EBs much smaller than other three lines (**Figure [1B](#F1){ref-type="fig"}**). After 4 days in suspension, EBs were transferred to cell culture plates for attachment and differentiation. This was the start of Stage 3, selection of nestin-positive NSCs. After 1 day in the ITSFn medium, all EBs from R1, 7Q, and 140Q lines attached and started to differentiate. However, less than half of HN EBs attached and showed little signs of differentiation (**Figure [1C](#F1){ref-type="fig"}**). Cells were cultured in ITSFn for seven more days. R1, 7Q, and 140Q lines continued to differentiate and NSCs spread across the entire culture plate (**Figure [1C](#F1){ref-type="fig"}**, Day 8). After several rounds of changes of the ITSFn medium over 8 days, only a low percentage of HN EBs remained attached, with limited differentiation. Nestin-positive NSCs (Stage 4) were expanded by collecting and replating the Day 8 ITSFn cells into N2 medium. On average, nearly 10-fold less cells were obtained from HN (**Figure [1C](#F1){ref-type="fig"}**; Table). After culturing for 6 days in the N2 medium, cells were stained for an NSC marker nestin. Nearly all differentiated cells expressed nestin (**Figure [1D](#F1){ref-type="fig"}**), indicating successful generation of NSCs. They were next differentiated into neurons/glia (Stage 5). A mixture of neurons (β-III tubulin-positive) and glia (GFAP-positive) was obtained from both R1 and 7Q lines (wild type for Htt, **Figure [1E](#F1){ref-type="fig"}**). Most of HN NSCs died leaving a few large cells stained positive for GFAP. For 140Q NSCs, cell death was observed during the final stage of differentiation (Stage 5, Day 4, **Figure [1E](#F1){ref-type="fig"}**; Supplementary Figure [2](#SM3){ref-type="supplementary-material"}), consistent with a previous report ([@B12]). In summary, cells with wild type or mutant Htt (R1, 7Q, and 140Q) were able to generate NSCs, but cells lacking Htt (HN) did not make the NSCs. Further, only wild type ES cells differentiated into neurons/glia.

![**Neural differentiation of mESC lines carrying different forms of Htt.** Using the 5-stage neural differentiation method, four mESC lines were differentiated into neurons/glia. Morphology of cells at different stages is shown. **(A)** Stage 1: mESCs. The pluripotency of mESCs was examined by the AP assay. **(B)** Stage 2: floating EBs at Day 3. **(C)** Stage 3: Selection of NSCs in ITSFn medium. EBs were plated onto cell culture plates for attachment and differentiation. Morphology of NSCs on Day 1 and Day 8 are shown. The average number of cells collected from one 100 mm dish after Stage 3 (ITSFn, Day 8) for each cell line is shown in the table. **(D)** Stage 4: Expansion of nestin-positive NSCs in N2 medium at Day 6. Anti-nestin (green) and TO-PRO-3 dye (blue, nuclei). **(E)** Stage 5: Differentiation of neurons/glia at Day 6 (R1, HN, 7Q) and Day 4 (140Q). Shown are β-III tubulin in red, GFAP in green, and TO-PRO-3 in blue. Scale bar: **(A--C)** 200 μm, **(D,E)** 25 μm.](fncel-11-00033-g001){#F1}

mESCs Lacking Htt Show Limited Capacity to Form Neural Progenitor Cells
-----------------------------------------------------------------------

The above results suggest a requirement for Htt in neural differentiation. We next employed differentiation protocols involving hanging-drop EB formation. A defined number of mESCs was used to form one EB so that all EBs generated would be of similar size ([@B48]). These protocols were used to produce progenitors of ectoderm, endoderm, and mesoderm lineages.

Neural progenitor cell differentiation (ectodermal lineage) was carried out in four mESC lines (**Figure [2A](#F2){ref-type="fig"}**). All made intact EBs (spheres); however, on average HN neural EBs were smaller in size (**Figure [2B](#F2){ref-type="fig"}**). Instead of using 60 mm Petri dishes, we modified the original protocol by transferring day 2 neural EBs to ultra low attachment 96-well plates. This way we could monitor floating EBs one by one under a microscope. For each EB, it was counted as 'formed' if it had a good spherical structure. The efficiency of EB formation, calculated as the number of EBs formed over EBs seeded, was similar for all four cell lines (around 95%, **Figure [2B](#F2){ref-type="fig"}**). After culturing in ultra low attachment 96-well plates for 3 days, bright field images of Day 5 neural EBs were captured. All EBs generated from R1, 7Q, and 140Q lines remained spherical, with an average diameter above 300 μm (**Figure [2C](#F2){ref-type="fig"}**). In contrast, HN neural EBs were much smaller (50% of R1 neural EBs) and appeared disorganized in structure. Day 5 neural EBs were transferred to cell culture plates for attachment and differentiation to NSCs in ITSFn medium. On Day 1 in the ITSFn medium, almost all R1, 7Q, and 140Q neural EBs attached to cell culture plates and started to differentiate. However, most HN neural EBs did not attach. Attached cells if any did not differentiate. Differentiation potential of neural EBs was calculated as the percentage of EBs attached and differentiated over the total number of EBs plated. HN neural EBs showed low efficiency of differentiation (\<10%), while R1, 7Q, and 140Q neural EBs efficiently generated NSCs (\>95%) (**Figure [2D](#F2){ref-type="fig"}**). NSC selection in ITSFn medium was carried out for 8 days. Only a few HN neural EBs attached to cell culture plates with no sign of differentiation (**Figure [2D](#F2){ref-type="fig"}**, Day 8). In contrast, neural EBs of R1, 7Q, and 140Q cell lines differentiated into NSCs and occupied nearly the entire plate.

![**Neural progenitor cell differentiation by the hanging-drop EB method (ectodermal lineage). (A)** Diagram showing the timeline of neural progenitor differentiation. **(B)** Morphology of floating EBs at Day 2. Graph at right shows efficiency of EB formation, calculated as the percentage of EBs formed over the total number of EBs seeded. R1: 95.62 ± 0.75, HN: 91.04 ± 7.41, 7Q: 94.37 ± 1.71, 140Q: 95.88 ± 2.88. No statistical significance. **(C)** Morphology and average diameter of Day 5 EBs cultured in ultra low attachment 96-well plate. ^∗∗∗∗^*P* \< 0.0001, compared to R1, 7Q, and 140Q, by one-way ANOVA test. *n* = 3 independent experiments. **(D)** Generation of NSCs. Morphology of NSCs cultured in ITSFn medium at Day 1 and Day 8. Differentiation potential of neural EBs was calculated as the percentage of EBs attached and differentiated over the total number of EBs plated. R1: 97.09 ± 4.47, HN: 7.60 ± 12.04, 7Q: 97.08 ± 4.76, 140Q: 95.31 ± 5.86. ^∗∗∗∗^*P* \< 0.0001, compared to R1, 7Q, and 140Q, by one-way ANOVA test. *n* = 3 independent experiments. Scale bar **(B--D)**: 200 μm. **(E)** Expression of different markers during neural progenitor cell differentiation. Quantitative RT-qPCR was performed for Nestin, Pax6, Oct4, Htt exon 16-17, and GAPDH using RNA collected from cells at different neural differentiation stages including mESC, EB (Day 5), and ITSFn (Day 8). Gene expression was calculated as fold change (over R1 mESC) after normalization to GAPDH expression. ^∗∗∗^*P* \< 0.001, compared to mESCs, by Dunnett's multiple comparisons test (one-way ANOVA). n.s., non-significant (*P* \> 0.05). Separate graphs for Oct4 and Htt exon 16-17 are shown in Supplementary Figure [3A](#SM4){ref-type="supplementary-material"}.](fncel-11-00033-g002){#F2}

Quantitative RT-qPCR was performed for Nestin, Pax6, Oct4, Htt exon 16-17, and GAPDH using RNA collected from cells at different neural differentiation stages (**Figure [2E](#F2){ref-type="fig"}**; Supplementary Figure [3A](#SM4){ref-type="supplementary-material"}). We found expression of Nestin elevated in R1, 7Q, and 140Q EBs (Day 5) and ITSFn NSCs (Day 8), but not in HN cells. Lack of Nestin induction in HN ITSFn NSCs agreed with the observation that HN was less efficient in generating NSCs compared to stem cells expressing wild type or mutant Htt. We also examined Pax6 levels during neural differentiation. In ITSFn NSCs, all four cell lines showed elevated Pax6, however, they were not statistically significant. At the mESC stage, all four cell lines showed expression of the pluripotent gene Oct4 (Supplementary Figure [3A](#SM4){ref-type="supplementary-material"}). Upon neural differentiation to EBs and ITSFn NSCs, Oct4 mRNA levels were dramatically reduced to less than 10% for R1, 7Q, and 140Q cells. By contrast HN cells maintained relatively high Oct4 expression in EBs (34%) and ITSFn NSCs (50%). This is consistent with the observation that HN EBs did not readily attach and differentiate into NSCs when floating EBs were placed in cell culture plates. As expected Htt (exon 16-17) expression in HN cells was 10-fold less than R1, 7Q, and 140Q cells at all stages of differentiation. The results suggest that HN mESCs have limited capacity in generating neural progenitor cells.

mESCs Lacking Htt Can Differentiate into Pancreatic and Cardiac Progenitor Cells
--------------------------------------------------------------------------------

We next sought to determine whether Htt is also required for endoderm and mesoderm differentiation. Cardiac progenitor differentiation (mesodermal lineage) was carried out on R1 and HN mESCs using the hanging-drop EB method, with 500 mES cells in each droplet (**Figure [3A](#F3){ref-type="fig"}**). At Day 4, cardiac EBs remained intact in both cell lines, although the size of HN cardiac EBs was smaller (**Figure [3B](#F3){ref-type="fig"}**). On Day 5, cardiac EBs were transferred to cell culture plates. Almost all EBs attached and differentiated over the following 2 weeks. Both R1 and HN mESCs differentiated into cardiac progenitor cells with similar morphology on Day 12 and Day 19 (**Figure [3B](#F3){ref-type="fig"}**). RT-qPCR analysis showed presence of cardiac progenitor-specific markers Nkx2.5 and αMHC in differentiated cells (**Figure [3C](#F3){ref-type="fig"}**). Interestingly, we found expression of the markers to be greater at Day 12 in HN cardiac progenitors compared with Day 19 cells, while R1 cells showed induction of these two markers as mESCs differentiated to Day 12 and Day 19 cardiac EBs. The observed difference suggests Htt may play a limited role in this process. At the mESC stage, both R1 and HN cells showed expression of the pluripotent gene Oct4 (Supplementary Figure [3B](#SM4){ref-type="supplementary-material"}). Upon cardiac progenitor cell differentiation, Oct4 mRNA levels were greatly reduced to about 10% or less in both cell lines. Immunocytochemistry of Desmin, a specific marker expressed in Day 11 cardiac EBs, showed positive staining in both R1 and HN Day 12 cardiac EBs (Supplementary Figure [4](#SM5){ref-type="supplementary-material"}). The results suggest that *Htt* is not required for cardiac progenitor cell differentiation under the experimental conditions used in this study.

![**Cardiac progenitor cell differentiation by the hanging-drop EB method (mesodermal lineage). (A)** Diagram showing the timeline of cardiac progenitor differentiation. **(B)** Morphology of R1 and HN cells during cardiac progenitor differentiation. Scale bar: 200 μm. **(C)** mRNA expression of cardiac progenitor cell-specific markers αMHC and Nkx2.5 at Day 12 and 19 was determined by quantitative RT-qPCR. Gene expression was calculated as fold change (over R1 mESC) after normalization to GAPDH expression. ^∗∗∗^*P* \< 0.001, ^∗∗^*P* \< 0.01, and ^∗^*P* \< 0.05, compared to the mESC group by Dunnett's multiple comparisons test (one-way ANOVA). Separate graphs for Oct4 and Htt exon 16-17 are shown in Supplementary Figure [3B](#SM4){ref-type="supplementary-material"}.](fncel-11-00033-g003){#F3}

Next, we carried out differentiation of R1 and HN mESCs into pancreatic progenitor cells (endodermal lineage) (**Figure [4A](#F4){ref-type="fig"}**). Similar to cardiac progenitor differentiation, pancreatic EBs formed from both cell lines, albeit those from HN EBs were smaller in size (**Figure [4B](#F4){ref-type="fig"}**). We found almost all pancreatic EBs attach and differentiate after plating Day 5 EBs onto cell culture plates. Similar morphologies were observed between R1 and HN differentiated cells (**Figure [4B](#F4){ref-type="fig"}**, Day 10). On Day 14, differentiated cells were collected and replated for further differentiation into pancreatic progenitors. Both R1 and HN cell lines gave rise to morphologically similar pancreatic progenitors as shown for Day 19 and Day 31 (**Figure [4B](#F4){ref-type="fig"}**). Quantitative RT-PCR analysis demonstrated mRNA expression of Isl1, a marker of pancreatic progenitors, in both R1 and HN differentiated cells at Day 20 and Day 35 (**Figure [4C](#F4){ref-type="fig"}**). Gcg (glucagon) is a pancreatic hormone whose expression appears at later stages of pancreatic progenitor cell differentiation. RT-qPCR data showed induction of Gcg in both R1 and HN pancreatic EBs after 20 days of differentiation. At Day 15, we observed differences in the levels of Isl1 and Gcg expression between R1 and HN cells, indicating the absence of Htt may have an effect on early stages of pancreatic differentiation. Nestin is also a marker during pancreatic differentiation. Its expression was found elevated dramatically in both R1 and HN EBs on Day 15 (\>20-fold). Nestin levels decreased gradually as pancreatic differentiation continued. At the mESC stage, both R1 and HN cells showed expression of the pluripotent gene Oct4 (Supplementary Figure [3C](#SM4){ref-type="supplementary-material"}). Upon pancreatic progenitor cell differentiation, Oct4 mRNA levels were greatly reduced to about 10% in both cell lines. The results suggest that *Htt* is also not required for pancreatic progenitor cell differentiation under the experimental conditions used in this study.

![**Pancreatic progenitor cell differentiation by the hanging-drop EB method (endodermal lineage). (A)** Diagram showing the timeline of pancreatic progenitor differentiation. **(B)** Morphology of R1 and HN cells during pancreatic progenitor differentiation. Scale bar: 200 μm. **(C)** mRNA expression of pancreatic progenitor cell-specific marker Isl1 and Gcg at Day 15, 20, and 35 was determined by quantitative RT-qPCR. Gene expression was calculated as fold change (over R1 mESC) after normalization to GAPDH expression. ^∗∗∗∗^*P* \< 0.0001, ^∗∗∗^*P* \< 0.001, ^∗∗^*P* \< 0.01, and ^∗^*P* \< 0.05, compared to the mESC group by Dunnett's multiple comparisons test (one-way ANOVA). Separate graphs for Oct4 and Htt exon 16-17 are shown in Supplementary Figure [3C](#SM4){ref-type="supplementary-material"}.](fncel-11-00033-g004){#F4}

In these experiments, 500 and 600 mES cells per droplet were used to generate cardiac and pancreatic EBs, respectively. Since neural EBs were made with 200 mESCs per droplet we repeated the experiment with 500 and 1000 mES cells per droplet (Supplementary Figure [5](#SM6){ref-type="supplementary-material"}). We observed HN Day 5 neural EBs slightly larger when the cell number increased from 500 to 1000 per droplet. However, they remained disorganized similar to HN neural EBs that were generated from 200 cells per droplet. Further differentiation in ITSFn medium (Day 1 and Day 6) showed that HN neural EBs from 500 or 1000 cells per droplet did not attach and differentiate into NSCs efficiently. Therefore, increasing the starting number of mESCs to generate neural EBs did not alter the poor efficiency of *Htt*-null cells in generating NSCs.

Transcriptional Profiles of R1 and HN mESCs by RNA-Seq
------------------------------------------------------

The neural differentiation experiments showed inefficient generation of NSCs from HN mESCs, suggesting *Htt* plays a critical role in this process. To investigate the basis for the lack of neural differentiation we carried out gene expression profiling by RNA-seq to examine if genes involved in neural differentiation were dysregulated in HN mESCs.

Using RNA isolated from undifferentiated R1 and HN mESCs, we performed 50 nucleotide paired-end total mRNA sequencing. Comparison of expression profiles between HN and R1 mESCs identified 51 up-regulated genes (log2 fold change \> 1, *p* \< 0.05) and 48 down-regulated genes (log2 fold change \< -1, *p* \< 0.05). **Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}** show top 20 up-regulated and down-regulated genes in HN mESCs. Validation of the RNA-seq data carried out by RT-qPCR demonstrated elevated expression of Olig2, Olig1, Nod1, Crisp1, and Sdc2 in HN mESCs (**Figure [5A](#F5){ref-type="fig"}**), while Maoa, Kdm6a, Fundc1, Ly6a, and Myof mRNA levels were found reduced in HN mESCs (**Figure [5B](#F5){ref-type="fig"}**). Immunoblotting confirmed increased levels of Olig2 protein and reduced levels of Kdm6a protein in the nucleus (**Figure [5C](#F5){ref-type="fig"}**).

###### 

Top 20 up-regulated genes in *Htt*-null mESCs (HN compared with R1).

  Gene symbol   Gene description                                                                                       log2 fold change   *p*-value   *p*-adj
  ------------- ------------------------------------------------------------------------------------------------------ ------------------ ----------- ----------
  Alg13         Asparagine-linked glycosylation 13 homolog (S. cerevisiae)                                             2.621              6.84E-28    2.40E-24
  Galnt6        UDP-*N*-acetyl-alpha-[D]{.smallcaps}-galactosamine:polypeptide *N*-acetylgalactosaminyltransferase 6   2.133              4.89E-12    4.03E-09
  Nod1          Nucleotide-binding oligomerization domain containing 1                                                 2.120              1.30E-10    8.68E-08
  Hist1h2bm     Histone cluster 1, H2bm                                                                                1.933              2.63E-28    1.85E-24
  Olig1         Oligodendrocyte transcription factor 1                                                                 1.883              5.60E-09    3.02E-06
  Snrpf         Small nuclear ribonucleoprotein polypeptide F                                                          1.744              7.25E-18    1.02E-14
  Mapt          Microtubule-associated protein tau                                                                     1.662              3.93E-12    3.44E-09
  Sdc2          Syndecan 2                                                                                             1.575              3.63E-08    1.64E-05
  B3galtl       Beta-1,3-galactosyltransferase-like                                                                    1.555              1.57E-08    7.61E-06
  Fam129a       Family with sequence similarity 129, member A                                                          1.542              3.10E-10    1.98E-07
  Ubd           Ubiquitin D                                                                                            1.472              2.78E-05    5.57E-03
  Uggt2         UDP-glucose glycoprotein glucosyltransferase 2                                                         1.468              7.54E-06    1.85E-03
  Cd68          CD68 molecule                                                                                          1.460              7.16E-13    7.18E-10
  Peg3          Paternally expressed 3                                                                                 1.458              5.40E-06    1.43E-03
  D2hgdh        [D]{.smallcaps}-2-hydroxyglutarate dehydrogenase                                                       1.420              7.07E-06    1.77E-03
  Fam25c        Family with sequence similarity 25, member C                                                           1.412              7.13E-17    9.09E-14
  Crisp1        Cysteine-rich secretory protein 1                                                                      1.318              1.83E-04    2.54E-02
  Tgds          TDP-glucose 4,6-dehydratase                                                                            1.294              1.28E-05    2.85E-03
  Olig2         Oligodendrocyte transcription factor 2                                                                 1.281              2.69E-04    3.52E-02
  Trim34a       Tripartite motif containing 34A                                                                        1.253              3.76E-04    4.59E-02

###### 

Top 20 down-regulated genes in *Htt*-null mESCs (HN compared with R1).

  Gene symbol   Gene description                         log2 fold change   *p*-value   *p*-adj
  ------------- ---------------------------------------- ------------------ ----------- ----------
  Maoa          Monoamine oxidase A                      -4.129             6.59E-45    9.25E-41
  Kdm6a         Lysine (K)-specific demethylase 6A       -3.481             5.22E-28    2.40E-24
  Fundc1        FUN14 domain containing 1                -3.030             6.62E-21    1.03E-17
  Hist1h4i      Histone cluster 1, H4i                   -2.290             1.53E-23    3.07E-20
  Tmem64        Transmembrane protein 64                 -1.931             5.54E-25    1.30E-21
  Khdc3         KH domain containing 3                   -1.851             3.43E-11    2.53E-08
  Htt           Huntingtin                               -1.838             4.05E-10    2.47E-07
  Myof          Myoferlin                                -1.769             5.92E-10    3.46E-07
  Hnf4a         Hepatocyte nuclear factor 4, alpha       -1.705             8.26E-07    2.47E-04
  Wdfy1         WD repeat and FYVE domain containing 1   -1.625             5.75E-16    6.72E-13
  Sfmbt2        Scm-like with four mbt domains 2         -1.607             1.88E-09    1.05E-06
  Pttg1         Pituitary tumor-transforming 1           -1.580             6.37E-09    3.31E-06
  Trh           Thyrotropin-releasing hormone            -1.568             1.08E-12    1.01E-09
  Hist1h2bp     Histone cluster 1, H2bp                  -1.537             5.50E-11    3.85E-08
  Adam23        ADAM metallopeptidase domain 23          -1.508             7.97E-08    3.27E-05
  Atp10d        ATPase, class V, type 10D                -1.489             1.94E-07    6.96E-05
  Anxa3         Annexin A3                               -1.399             1.11E-05    2.55E-03
  Crxos1        Crx opposite strand transcript 1         -1.350             1.27E-04    1.94E-02
  Eras          ES cell expressed Ras                    -1.311             7.58E-08    3.22E-05
  Fbxo2         F-box protein 2                          -1.289             5.61E-05    9.59E-03

![**Differentially expressed genes in R1 and *Htt*-null mESCs. mRNA levels of genes (A)** up-regulated or **(B)** down-regulated in HN mESCs compared with R1 cells were confirmed by quantitative RT-qPCR. Gene expression was calculated as relative expression after normalization to18S rRNA. All experiments were carried out using RNA samples extracted from four different batches of R1 and HN mESCs (*N* = 4). ^∗∗∗∗^*P* \< 0.0001, ^∗∗^*P* \< 0.01, and ^∗^*P* \< 0.05, compared to R1, by unpaired *t*-test. a.u., arbitrary units. **(C)** Protein levels of Olig2 and Kdm6a were examined by immunoblotting. Vinculin and YY1 served as markers of cytoplasmic and nuclear fractions, respectively. ^∗^Kdm6a (170 kD), ^∗∗^Olig2 (32 kD).](fncel-11-00033-g005){#F5}

We used Gene Set Enrichment Analysis ([@B37]; [@B54]) to compare up-regulated genes in HN mESCs with curated gene sets within the C2 collection of the Molecular Signatures Database ([@B54]). We found most enriched signature "Genes up-regulated in mouse ES cells with deficient SUZ12" (**Table [3](#T3){ref-type="table"}**). SUZ12 is a component of Polycomb Repressive Complex 2 (PRC2). Interestingly, Olig2, reported repressed by PRC1 and PRC2 in mESCs ([@B9]), is de-repressed in HN mESCs (**Figure [5A](#F5){ref-type="fig"}**; **Table [1](#T1){ref-type="table"}**). Because there was a published report suggesting a link between Htt and components of the PRC2 complex ([@B50]), we asked whether Htt repressed the activation of Olig1 and Olig2 genes through the PRC2 complex. We performed chromatin immunoprecipitation analysis in R1 mESCs and failed to detect co-occupancy of Htt and Ezh2 (component of PRC2) at the Olig1 and Olig2 promoter regions (Supplementary Figure [6](#SM7){ref-type="supplementary-material"}).

###### 

Gene Set Enrichment Analysis finds ES cells with deficient SUZ12 share similar enriched signatures of up-regulated genes with *Htt*-null mESCs.

  Gene Set Name             \# Genes in Gene Set (K)   Description                                                                                \# Genes in Overlap (k)   k/K        *p*-value   FDR *q*-value
  ------------------------- -------------------------- ------------------------------------------------------------------------------------------ ------------------------- ---------- ----------- ---------------
  PASINI_SUZ12_TARGETS_UP   112                        Genes up-regulated in ES (embryonic stem cells) with deficient SUZ12 \[GeneID = 23512\].   15                        0.1339     9.54E-18    4.51E-14
                                                                                                                                                                                                   
                                                                                                                                                                                                   
                                                                                                                                                                                                   
  HTRA1                     LAPTM5                     NROB1                                                                                      NFATC2IP                  C17orf48               
  SPP1                      LAMA1                      H19                                                                                        RPP25                     CYCTP                  
  TMEM40                    PRDM14                     AQP3                                                                                       C17orf96                  TEX15                  

List of overlapping genes are shown above.

Discussion
==========

Phenotypic Differences between Wild Type and Mutant Htt in Neural Differentiation
---------------------------------------------------------------------------------

In this study, we examined a role of Htt in neural differentiation *in vitro* using the 5-stage neural differentiation method in four mESC lines carrying different forms of Htt. Our data show that Htt is required for neural differentiation of mESCs. Htt is not needed for mesoderm or endoderm progenitor differentiation. RNA-seq analysis shows candidate dysregulated genes that may be involved in the inefficient NSC generation in mESCs lacking Htt.

Compared to wild type or mutant Htt-expressing cell lines (R1, 7Q, and 140Q), *Htt* nullizygous mESCs are not prone to generating NSCs as shown by small EB size and low tendency to attach to a plate and differentiate into NSCs. Further differentiation of HN NSCs to neurons/glia resulted in massive cell loss and formation of a few giant GFAP-positive cells. This observation is consistent with a recent report demonstrating that absence of Htt in mESCs promotes NSC differentiation into glial cell fate ([@B12]). This conclusion is based on the increase of GFAP-positive cells at the terminal neuronal differentiation stage. In their report, both wild type and *Htt*-null ES cells generated similar numbers of NSCs. However, our data show that HN mESCs have limited capacity for generating NSCs. The discrepancy may be explained by different neural differentiation protocols used. [@B12] used a monolayer differentiation method ([@B51]), while we adopted the 5-stage neural differentiation protocol involving EB formation.

In contrast, neural EBs expressing mutant Htt (140Q) attached more readily to plates and differentiated into NSCs. Further differentiation of 140Q NSCs into neurons/glia resulted in cell death. These results agree with studies demonstrating that presence of polyQ-expanded Htt increases neural differentiation of embryonic and NSCs ([@B29]), and cells with mutant polyQ Htt undergo cell death during neuronal differentiation ([@B12]).

Studies by [@B40] found *Htt*-KO ESCs to be impaired for survival and specification of all three germ layers during EB formation and under inductive conditions, suggesting Htt is required for neural and non-neural differentiation. In contrast, mutant *Htt*-expressing cells showed alterations in stage-specific developmental events. The HN ESCs we examined were defective for differentiation into neural lineage, but not cardiac or pancreatic lineages. The *Htt*-KO ESCs used by above authors are deleted of exons 4 and 5 in the murine *Htt* gene ([@B17]). The HN ESCs used in this study were created by deleting the promoter and exon 1 sequence of *Htt* ([@B64]). Our 5-stage differentiation protocol also differed from the neural induction protocol used by [@B40]. These differences may account for the different outcomes of ESCs undergoing differentiation. At a molecular level we observed differences in mRNA expression of cardiac and pancreatic progenitor markers between wild type and *Htt*-null cells. Thus, *Htt* appears to play a role in the pattern of gene expression through different stages of differentiation of cardiac and pancreatic progenitors.

Transcriptional Profiling of mESCs Lacking *Htt*
------------------------------------------------

The most down regulated gene in *Htt* null cells is MaoA, an enzyme that degrades amine neurotransmitters such as serotonin, dopamine, and noradrenalin. Its deficiency causes excess production of monoamine neurotransmitters resulting in enhanced aggressiveness in mice and humans ([@B10]; [@B1]). Changes in the dopaminergic system have been correlated with HD pathogenesis ([@B11]; [@B49]). Using well characterized immortalized mouse striatal cell lines ST*Hdh*^Q7/Q7^ and ST*Hdh*^Q111/Q111^, MaoA expression and activity were found elevated in cells expressing mutant Q111 Htt ([@B42]). ST*Hdh*^Q111/Q111^ cells also showed enhanced susceptibility to stress and cell death. Interestingly, a recent study found polymorphisms in the *MAOA* gene as modifiers of psychiatric and cognitive symptoms in HD patients ([@B58]). MaoA may play a regulatory role in neural differentiation as mouse ES cells lacking *MaoA* show reduced differentiation to neural cells compared to wild type ([@B60]). Similar mechanisms may be responsible for the poor neural differentiation of *Htt*-null ES cells reported in this study.

Oligodendrocyte transcription factor 1 and 2 (Olig1 and Olig2) are basic helix-loop-helix transcription factors that promote oligodendrocyte specification in early neural progenitor cells. They were found up regulated in HN cells. It has been shown that Olig2 is repressed by polycomb repressive complexes in mESCs ([@B9]). In a transgenic mouse model in which Olig2 was overexpressed in NSCs, severe defects in brain development and massive neuronal cell death of cortical progenitors were observed ([@B28]). Olig2 was shown to target enhancers of neurogenic genes and inhibit cortical neurogenesis. A recent mouse study revealed that Brg1, a subunit of the SWI/SNF chromatin remodeling complex, interacts with the Olig2 promoter and represses Olig2 expression in the cortex ([@B32]). Although *Brg1*-null neural progenitor cells show early expression of Olig2 in the cortex, they fail to differentiate into oligodendrocyte progenitors. These studies suggest elevated levels of Olig2 in neural progenitor cells cause dysregulated neurogenesis or neuronal cell death.

A previous study examined gene expression profiles of mESCs with and without Htt ([@B53]). Microarray analysis showed diminished expression of vital patterning genes including *Lefty1, Otx2*, and *Pem* (*Rhox5*), as well as increased lysosomal activity genes such as *Casp8* and *Psmd8* in *Htt*-null mESCs (by at least twofold). We also found similar expression patterns of these genes in HN mESCs; however, fold changes were minimal (less than twofold). Although HN mESCs are the same in both studies, differences in gene expression profiling may be due to cell culture conditions and analytical methods used. We adopted the "3i + mLIF" formula to maintain the pluripotency of mESCs ([@B62]). Two additional studies reported RNA profiling of *Htt*-null cells by microarray ([@B22]) and RNA-seq ([@B6]). We compared our RNA-seq data with the microarray study; however, we did not find any overlapping genes dysregulated by at least twofold. As mentioned above an important difference is that the cell line used in their study was the *Htt*-dKO ESCs (exon 4/5 deletion), while the HN ESCs used in our study were deleted of the promoter and exon 1 sequence. There may exist subtle molecular differences between the two cell lines.

We used Gene Set Enrichment Analysis to compare up-regulated genes in HN ESCs with curated gene sets in the Molecular Signatures Database. The most enriched signature was found in the up-regulated genes in mouse ES cells deficient of SUZ12, a component of the PRC2 repressor complex (**Table [3](#T3){ref-type="table"}**). A link between PRC2 and HD has been reported. A recent genome-wide ChIP study for the H3K4me3 histone mark found altered enrichment in postmortem prefrontal cortex of HD patient samples compared with control brains ([@B15]). They also reported depletion of the PRC2 repressive state in H3K4me3-enriched peaks in HD, suggesting epigenetic modifications contribute to dysregulated gene expression associated with neurodegeneration. Further, PRC2 deficiency in striatal neurons resulted in transcriptional changes leading to neurodegeneration in mice ([@B59]). Although PRC2 has been shown to be a direct target of Htt ([@B50]), we did not detect co-occupancy of Htt and Ezh2 (component of PRC2) at Olig1 and Olig2 promoter regions. Nevertheless, the finding that the transcriptional profile of *Htt*-null ES cells is most similar to that of cells lacking a PRC2 component lends further support to the idea that epigenetic gene regulation plays a role in HD pathogenesis.
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EBs

:   embryoid bodies

GFAP

:   glial fibrillary acidic protein

HD

:   Huntington's disease
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:   lysine-specific demethylase 6A
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